References
Alpaydin, E. (2021). Machine learning. MIT Press.
An, G., & Cockrell, C. (2022). Drug development digital twins for drug discovery, testing, and repurposing: A schema for requirements and development. Frontiers in Systems Biology, 2, 928387.
Arden, N. S., et al. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. International Journal of Pharmaceutics, 602, 120554.
Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L. (2019). Using artificial intelligence methods to speed up drug discovery. Expert Opinion on Drug Discovery, 14(8), 769–777.
Arnold, M., et al. (2024). Machine learning for personalized depression treatment selection. Journal of Affective Disorders, 356, 123–131.
Atomwise. (2023). Predicting drug safety using AI. Atomwise Newsroom.
Bansal, V., et al. (2022). Machine learning in medical imaging. Journal of Clinical Imaging Science, 12(1), 23.
Barrett, J. S., Oskoui, S. E., Russell, S., & Borens, A. (2023). Digital research environment (DRE)-enabled artificial intelligence (AI) to facilitate early stage drug development. Frontiers in Pharmacology, 14, 1115356.
Bai, F., Li, S., & Li, H. (2024). AI enhances drug discovery and development. National Science Review, 11, nwad303.
Ball, R., & Dal Pan, G. (2022). "Artificial intelligence" for pharmacovigilance: Ready for prime time? Drug Safety, 45, 429–438.
Baronzio, G. (2015). Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid. Frontiers in Oncology, 5, 165.
Bhinder, B., Gilvary, C., Madhukar, N. S., & Elemento, O. (2021). Artificial intelligence in cancer research and precision medicine. Cancer Discovery, 11, 900–915.
Blasiak, A. (2020). CURATE.AI: Optimizing personalized medicine with artificial intelligence. SLAS Technology, 25(2), 95–105.
Brown, N. (2015). In silico medicinal chemistry: Computational methods to support drug design. Royal Society of Chemistry.
Burki, T. (2019). Pharma blockchains AI for drug development. The Lancet, 393(10185), 2382.
Cai, X., Lin, Y., Li, Y., Wang, R., & Ke, C. (2025a). Set point regulation control for KdVB equation. In 37th Chinese Control and Decision Conference (pp. 5716–5720).
Cai, X., Lin, Y., Li, Y., Zhang, L., & Ke, C. (2025b). Inverse optimal adaptive boundary control for heat PDE. In 37th Chinese Control and Decision Conference (pp. 1825–1828).
Cai, X., Li, Y., Wang, P., Lin, Y., Zhang, L., & Liu, L. (2025c). Adaptive inverse optimal control for unstable reaction-diffusion PDE system. Kybernetika, 61(4), 537–553.
Chakravarty, K., Antontsev, V. G., Khotimchenko, M., Gupta, N., Jagarapu, A., Bundey, Y., Hou, H., Maharao, N., & Varshney, J. (2021). Accelerated repurposing and drug development of pulmonary hypertension therapies for COVID-19 treatment using an AI-integrated biosimulation platform. Molecules, 26(7), 1912.
Chan, H. S. (2019). Advancing drug discovery via artificial intelligence. Trends in Pharmacological Sciences, 40(8), 592–604.
Chang, W. T., et al. (2022). An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline. Archives of Toxicology, 96, 2731–2737.
Ciallella, H. L., & Zhu, H. (2019). Advancing computational toxicology in the big data era by artificial intelligence: Data-driven and mechanism-driven modeling for chemical toxicity. Chemical Research in Toxicology, 32(3), 536–547.
Connor, S., Li, T., Roberts, R., Thakkar, S., Liu, Z., & Tong, W. (2022). Adaptability of AI for safety evaluation in regulatory science: A case study of drug-induced liver injury. Frontiers in Artificial Intelligence, 5, 1034631.
Davenport, T., & Kalakota, R. (2019). The potential for AI in healthcare. Future Healthcare Journal, 6(2), 94–98.
Dercle, L., et al. (2020). Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics. Clinical Cancer Research, 26, 2151–2162.
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33.
Dong, Z., Long, Q., Zhou, Y., Wang, P., Zhu, Z., Luo, X., Wang, Y., Wang, P., & Zhou, Y. (2024). PIXEL: Prompt-based zero-shot hashing via visual and textual semantic alignment. In Proceedings of CIKM 2024.
Esteva, A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118.
Exscientia. (2023). Advancements in AI-designed molecules. Exscientia Press Release.
FDA. (2024). FDA's digital health innovation plan.
Fetzer, J. H. (1990). What is artificial intelligence? In J. H. Fetzer (Ed.), Artificial intelligence: Its scope and limits (pp. 3–27). Springer.
Firth, N. C., Brown, N., & Blagg, J. (2015). MOARF, an integrated workflow for multiobjective optimization: Implementation, synthesis, and biological evaluation. Journal of Chemical Information and Modeling, 55(6), 1169–1180.
Flatiron Health. (2023). AI in personalized medicine. Flatiron Health Reports.
Gallego, V., Naveiro, R., Roca, C., Rios Insua, D., & Campillo, N. E. (2021). AI in drug development: A multidisciplinary perspective. Molecular Diversity, 25, 1461–1479.
Garbarino, S., & Bragazzi, N. L. (2024). Personalized sleep medicine: AI-driven diagnosis and management of sleep disorders. Sleep Medicine Reviews, 73, 101870.
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., & Schneider, N. (2021). Utilizing graph machine learning within drug discovery and development. Briefings in Bioinformatics, 22(6), bbab159.
Gerke, S., Minssen, T., & Cohen, G. (2020). Ethical and legal challenges of AI-driven healthcare. Artificial Intelligence in Medicine, 103, 101791.
Gholap, A. D., et al. (2024). Deep learning models for drug candidate optimization in pharmaceutical development. Journal of Pharmaceutical Sciences, 113(2), 345–356.
Gibbs, B., et al. (2020). NLP in clinical documentation and decision-making. Journal of Biomedical Informatics, 102, 103356.
Grangeia, H. B., et al. (2020). Quality by design (QbD) in pharmaceutical development. European Journal of Pharmaceutics and Biopharmaceutics, 156, 85–95.
Haeberle, H. S., et al. (2019). Artificial intelligence in medical imaging and surgery. Journal of Healthcare Engineering, 2019.
Hao, Y., Lynch, K., Fan, P., Jurtschenko, C., Cid, M., Zhao, Z., & Yang, H. S. (2023). Development of a machine learning algorithm for drug screening analysis on high-resolution UPLC-MSE/QTOF mass spectrometry. Journal of Applied Laboratory Medicine, 8(1), 53–66.
Hasanzadeh, M., et al. (2022). AI-enhanced drug discovery and screening. Drug Discovery Today, 27(2), 511–523.
Hay, M., et al. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology, 32(1), 40–51.
Healx. (2023). AI in rare disease therapies. Healx Reports.
Hill, A., True, J. M., & Jones, C. H. (2024). Transforming drug development with synthetic biology and AI. Trends in Biotechnology, 42(11), 1072–1075.
Hong, E., Jeon, J., & Kim, H. U. (2023). Recent development of machine learning models for the prediction of drug-drug interactions. Korean Journal of Chemical Engineering, 40(2), 276–285.
Huang, Z., Shen, Y., Li, J., Fey, M., & Brecher, C. (2021). A survey on AI-driven digital twins in Industry 4.0: Smart manufacturing and advanced robotics. Sensors, 21(21), 6340.
Iorio, F., et al. (2016). A landscape of pharmacogenomic interactions in cancer. Cell, 166, 740–754.
IQVIA. (2022). Adaptive trials: The role of AI. IQVIA Insights.
Jain, N., & Jain, G. K. (2015). In silico de novo design of novel NNRTIs: A bio-molecular modelling approach. RSC Advances, 5, 14814–14827.
Johannet, P., et al. (2021). Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma. Clinical Cancer Research, 27, 131–140.
Jumper, J., et al. (2021). AlphaFold: Revolutionizing protein structure prediction. Nature.
Kargarandehkordi, A., et al. (2024). Real-time modeling of stress-related blood pressure fluctuations using wearable devices and AI. Journal of Hypertension, 42(3), 456–465.
Kuenzi, B. M., et al. (2020). Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell, 38, 672–684.
King, R. D. (1995). Machine learning and inductive logic programming. ACM Computing Surveys, 27(3), 340–372.
Lam, B., et al. (2021). Using wearable activity trackers to predict type 2 diabetes: Machine learning-based study. JMIR Diabetes, 6, e23364.
Lamy, C., et al. (2018). Machine learning-guided optimization of aerosol formulations for pulmonary drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 130, 156–165.
Le, N. Q. K., et al. (2024). Recent progress in machine learning approaches for predicting carcinogenicity in drug development. Expert Opinion on Drug Metabolism & Toxicology, 20, 621–628.
LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. Nature, 521(7553), 436–444.
Li, E., & Ajuwon, K. M. (2021). Mechanism of endocytic regulation of intestinal tight junction remodeling during nutrient starvation in jejunal IPEC-J2 cells. The FASEB Journal, 35(2), e21356.
Li, E., Horn, N., & Ajuwon, K. M. (2021). Mechanisms of deoxynivalenol-induced endocytosis and degradation of tight junction proteins in jejunal IPEC-J2 cells involve selective activation of the MAPK pathways. Archives of Toxicology, 95(6), 2065–2079.
Li, E., Horn, N., & Ajuwon, K. M. (2022). EPA and DHA inhibit endocytosis of claudin-4 and protect against deoxynivalenol-induced intestinal barrier dysfunction through PPARγ dependent and independent pathways. Food Research International, 157, 111420.
Li, E., Li, C., Horn, N., & Ajuwon, K. M. (2023a). Quercetin attenuates deoxynivalenol-induced intestinal barrier dysfunction by activation of Nrf2 signaling pathway in IPEC-J2 cells and weaned piglets. Current Research in Toxicology, 5, 100122.
Li, E., Li, C., Horn, N., & Ajuwon, K. M. (2023b). PPARγ activation inhibits endocytosis of claudin-4 and protects against deoxynivalenol-induced intestinal barrier dysfunction in IPEC-J2 cells and weaned piglets. Toxicology Letters, 375, 8–20.
Li, H., et al. (2023). AI-enabled delivery of mRNA for Alzheimer's disease treatment. Neuroscience Bulletin, 39(4), 563–574.
Li, Y. (2021). Physics-based simulation of tablet disintegration and dissolution. PhD thesis, Purdue University.
Li, Y. (2025g). Physics-informed neural networks for enhanced interface preservation in lattice Boltzmann multiphase simulations. In 2025 International Conference on Artificial Intelligence, Computer, Data Sciences and Applications (ACDSA).
Li, Y. (2025h). LBM-GNN: Graph neural network enhanced Lattice Boltzmann method. In 2025 International Conference on Artificial Intelligence, Computer, Data Sciences and Applications (ACDSA).
Li, Y., & Li, T. (2019). Integrating Lattice Boltzmann and bonded particle models to simulate tablet disintegration and dissolution. In NIPTE Annual Meeting.
Li, Y., Dong, J., Dong, Z., Yang, C., & Xu, Y. (2025b). SRKD: Towards efficient 3D point cloud segmentation via structure- and relation-aware knowledge distillation. arXiv:2506.17290.
Li, Y., Dong, Z., Yang, C., & Xu, Y. (2025d). AMMKD: Adaptive multimodal multi-teacher distillation for lightweight vision-language models. arXiv:2509.00039.
Li, Y., Lin, X., Zhang, K., Yang, C., Guo, Z., Gou, J., & Li, Y. (2025e). FedKD-hybrid: Federated hybrid knowledge distillation for lithography hotspot detection. arXiv:2501.04066.
Li, Y., Liu, S., & Xu, Z. (2025i). Spectral decomposition PINN-LBM for high Reynolds number turbulence simulation. In 9th Computational Methods in Systems and Software (CoMeSySo2025), Springer.
Li, Y., Long, Q., Zhou, Y., Zhang, R., Ning, Z., Zhu, Z., Zhou, Y., Wang, X., & Xiao, M. (2025f). COMAE: Comprehensive attribute exploration for zero-shot hashing. In Proceedings of ICMR 2025.
Li, Y., Lu, Y., Dong, Z., Yang, C., Chen, Y., & Gou, J. (2024a). SGLP: A similarity guided fast layer partition pruning for compressing large deep models. arXiv:2410.14720.
Li, Y., Li, K., Yin, X., Yang, Z., Dong, J., Dong, Z., Yang, C., Tian, Y., & Lu, Y. (2025a). SepPrune: Structured pruning for efficient deep speech separation. arXiv:2505.12079.
Li, Y., Yang, C., Dong, J., Yao, Z., Xu, H., Dong, Z., Zeng, H., An, Z., & Tian, Y. (2025c). Frequency-aligned knowledge distillation for lightweight spatiotemporal forecasting. arXiv:2507.02939.
Li, Y., Yang, C., Zeng, H., Dong, Z., An, Z., Xu, Y., Tian, Y., & Wu, H. (2025d). Frequency-aligned knowledge distillation for lightweight spatiotemporal forecasting. arXiv:2507.02939.
Liu, D., et al. (2019). Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade. Nature Medicine, 25, 1916–1927.
Liu, Q., Huang, R., Hsieh, J., Zhu, H., Tiwari, M., Liu, G., Jean, D., ElZarrad, M. K., Fakhouri, T., Berman, S., & Wang, Y. (2023). Landscape analysis of the application of artificial intelligence and machine learning in regulatory submissions for drug development from 2016 to 2021. Clinical Pharmacology & Therapeutics, 113(4), 771–774.
Liu, S., Wang, Y., & He, H. (2020). A new playing method of the guessing football lottery. IOP Conference Series: Materials Science and Engineering, 790(1), 012100. https://doi.org/10.1088/1757-899x/790/1/012100
Liu, Y., et al. (2020). Predictive analytics in healthcare. Journal of the American Medical Informatics Association, 27(4), 553–562.
Liu, Z., Roberts, R. A., Lal-Nag, M., Chen, X., Huang, R., & Tong, W. (2021). AI-based language models powering drug discovery and development. Drug Discovery Today, 26(11), 2593–2607.
Lloyd, L. (2024). AI for drug discovery. Nature Reviews Urology, 21, 517.
Low, Z. Y., Farouk, I. A., & Lal, S. K. (2020). Drug repositioning: New approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak. Viruses, 12(9), 1058.
Luo, Y., Peng, J., & Ma, J. (2022). Next decade's AI-based drug development features tight integration of data and computation. Health Data Science, 2022, 9816939.
Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today, 24(3), 773–780.
Mak, K.-K., Wong, Y.-H., & Pichika, M. R. (2024). Artificial intelligence in drug discovery and Development. In F. J. Hock & M. K. Pugsley (Eds.), Drug discovery and evaluation: Safety and pharmacokinetic assays (pp. 1461–1498). Springer.
Marques, L., et al. (2024). Advancing precision medicine: A review of in silico approaches. Pharmaceutics, 16, 332.
Mesko, B., & Topol, E. J. (2023). The imperative for regulatory oversight of large language models (or generative AI) in healthcare. NPJ Digital Medicine, 6, 120.
Momeni, K., et al. (2024). Machine learning prediction of tablet disintegration times during pre-formulation. International Journal of Pharmaceutics, 651, 123456.
Mukherjee, D., Roy, D., & Thakur, S. (2024). Transforming cancer care: The impact of AI-driven strategies. Current Cancer Drug Targets, 24, 1–4.
Niazi, S. K. (2023). The coming of age of AI/ML in drug discovery, development, clinical testing, and manufacturing: The FDA perspectives. Drug Design, Development and Therapy, 17, 2691–2725.
Pankevich, D. E., et al. (2014). Improving drug development for nervous system disorders. Neuron, 84(3), 546–553.
Patil, S., et al. (2023). AI in pharmaceutical regulatory science. Regulatory Toxicology and Pharmacology, 137, 105359.
Pereira, J. C., Caffarena, E. R., & dos Santos, C. N. (2016). Boosting docking-based virtual screening with deep learning. Journal of Chemical Information and Modeling, 56(12), 2495–2506.
Roche, V., Robert, J. P., & Salam, H. (2023). A holistic AI-based approach for pharmacovigilance optimization from patients' behavior on social media. Artificial Intelligence in Medicine, 144, 102638.
Rouse, M. (2017). IBM Watson supercomputer. TechTarget SearchEnterpriseAI.
Russell, S. J., & Norvig, P. (2016). Artificial intelligence: A modern approach. Pearson.
Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N. M., Das, D., Bidarolli, M., & Sony, H. T. (2023). Artificial intelligence and machine learning technology driven modern drug discovery and development. International Journal of Molecular Sciences, 24(3), 2026.
Schalkamp, A. K., et al. (2023). Wearable-based Parkinson's disease severity monitoring using deep learning. Nature Medicine, 29, 135–144.
Schuhmacher, A., et al. (2019). AI in pharmaceutical R&D management. Drug Discovery Today, 24(4), 892–898.
Schuhmacher, A., et al. (2021). AI-driven pharmacovigilance systems. Expert Opinion on Drug Safety, 20(10), 1231–1240.
Sellwood, M. A., Ahmed, F., Segler, M. H. S., & Brown, N. (2018). Artificial intelligence in drug discovery. Future Medicinal Chemistry, 10(17), 2025–2028.
Serrano, D. R., et al. (2023). AI-integrated 3D printing for customized polypills. Pharmaceutics, 15(8), 2100.
Sexton, J. Z., Fursmidt, R., O'Meara, M. J., Omta, W., Rao, A., Egan, D. A., & Haney, S. A. (2004). Machine learning and assay development for image-based phenotypic profiling of drug treatments. In S. Markossian et al. (Eds.), Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences.
Sheu, Y. H., et al. (2023). AI-assisted prediction of differential response to antidepressant classes. NPJ Digital Medicine, 6, 73.
Stankoski, S., et al. (2021). Smartwatch-based eating detection. Sensors, 21, 1902.
Stebbing, J., et al. (2020). Baricitinib in COVID-19 treatment. Lancet.
Talat, M., et al. (2023). AI for antimicrobial drug discovery. Journal of Antimicrobial Chemotherapy, 78(1), 15–27.
Tempus. (2023). AI applications in clinical trials. Tempus Blog.
Vora, L. K., et al. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics, 15(7), 1916.
Vyas, M. (2018). Artificial intelligence: The beginning of a new era in pharmacy profession. Asian Journal of Pharmaceutics, 12(1), 72–76.
Walsh, G. R., et al. (2018). AI-driven formulation development in pharmaceutical manufacturing. Pharmaceutical Research, 35(11), 213.
Wang, Y., Xing, J., Xu, Y., Zhou, N., Peng, J., Xiong, Z., & Lu, A. (2015). A comparative study of family-specific protein-ligand complex affinity prediction based on random forest approach. Journal of Computer-Aided Molecular Design, 29(4), 349–360.
Xing, L., Li, Y., & Li, T. (2019). Local concentrating, not shear stress, that may lead to possible instability of protein molecules during syringe injection: A fluid dynamic study with two-phase flow model. PDA Journal of Pharmaceutical Science and Technology, 73(3), 260–275.
Xue, H., et al. (2018). Review of drug repositioning approaches and resources. International Journal of Biological Sciences, 14(10), 1232.
Yun, Y. H., et al. (2015). AI in clinical trial design. Journal of Controlled Release, 219, 182–194.
Zeng, H., Li, Y., Niu, R., Yang, C., & Wen, S. (2025). Enhancing spatiotemporal prediction through the integration of Mamba state space models and diffusion transformers. Knowledge-Based Systems.
Zhang, L., Tan, J., Han, D., & Zhu, H. (2017). From machine learning to deep learning: Progress in machine intelligence for rational drug discovery. Drug Discovery Today, 22(11), 1680–1685.
Zhao, Y., et al. (2023). Detecting adverse drug reactions using AI. BMC Medical Informatics and Decision Making, 23, 75.
Zhu, H. (2020). Big data and artificial intelligence modeling for drug discovery. Annual Review of Pharmacology and Toxicology, 60, 573–589.